5,090 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by One Wealth Capital Management LLC

One Wealth Capital Management LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 5,090 shares of the company’s stock, valued at approximately $438,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Diversified Trust Co grew its stake in shares of Novo Nordisk A/S by 13.9% in the fourth quarter. Diversified Trust Co now owns 3,246 shares of the company’s stock valued at $279,000 after buying an additional 395 shares in the last quarter. Norman Fields Gottscho Capital Management LLC grew its position in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares during the period. Doliver Advisors LP increased its stake in shares of Novo Nordisk A/S by 54.5% during the 4th quarter. Doliver Advisors LP now owns 16,225 shares of the company’s stock worth $1,396,000 after purchasing an additional 5,721 shares during the last quarter. CWA Asset Management Group LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at about $2,722,000. Finally, Versant Capital Management Inc bought a new position in Novo Nordisk A/S during the fourth quarter worth about $86,000. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on NVO shares. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NVO traded down $2.01 during mid-day trading on Tuesday, hitting $83.02. 7,498,431 shares of the company’s stock were exchanged, compared to its average volume of 6,482,653. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm has a market cap of $372.55 billion, a price-to-earnings ratio of 26.87, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The stock’s 50-day simple moving average is $102.51 and its 200-day simple moving average is $120.68. Novo Nordisk A/S has a 52 week low of $81.50 and a 52 week high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.